PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.04
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
5628.35
P/S of 5628.35 while GNPX has no sales. Bruce Berkowitz would examine revenue quality advantage.
1.76
P/B 1.1-1.25x GNPX's 1.52. Bill Ackman would demand evidence of superior asset utilization.
-25.62
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-25.62
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
1.76
Fair value ratio 1.1-1.25x GNPX's 1.52. Bill Ackman would demand evidence of superior economics.
-6.19%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-3.90%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.